CareLit · DOI-Nachweis · Pneumologie
Safety and tolerability of once-daily tiotropium Respimat® add-on to at least inhaled corticosteroid maintenance therapy in adolescent patients with moderate or severe symptomatic asthma
DOI 10.1055/s-0036-1572092
Bibliografische Angaben
Nachweis in CareLit
Autor:innenE Beck, R Dahl, SJ Szefler, J Bernstein, M Vandewalker, M Engel, P Moroni-Zentgraf, A Unseld, E Hamelmann
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Once-daily tiotropium Respimat® add-on to at least ICS has demonstrated efficacy, safety and tolerability in adult patients across severities of asthma. We assess the safety and tolerability of once-daily tiotropium Respimat® in adolescent patients aged 12 – 17 years with moderate or severe symptomatic asthma. Method: Two Phase III, randomised, double-blind, parallel-group trials. RubaTinA-asthma® (NCT01…
Zitieren
Zitierempfehlung
E Beck, R Dahl, SJ Szefler, J Bernstein, M Vandewalker, M Engel, P Moroni-Zentgraf, A Unseld, E Hamelmann (2016) Safety and tolerability of once-daily tiotropium Respimat® add-on to at least inhaled corticosteroid maintenance therapy in adolescent patients with moderate or severe symptomatic asthma. Pneumologie (02). https://doi.org/10.1055/s-0036-1572092
Mit CareLit weiterarbeiten